


SDMA

Cat. No.:	HY-101410		
CAS No.:	30344-00-4		
Molecular Formula:	C ₈ H ₁₈ N ₄ O ₂		
Molecular Weight:	202.25		
Target:	Endogenous Metabolite		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 67.5 mg/mL (333.75 mM; Need ultrasonic)
 H₂O : 50 mg/mL (247.22 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent		Mass		
	Concentration		1 mg	5 mg	10 mg
	1 mM		4.9444 mL	24.7219 mL	49.4438 mL
	5 mM		0.9889 mL	4.9444 mL	9.8888 mL
	10 mM		0.4944 mL	2.4722 mL	4.9444 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: PBS
Solubility: 120 mg/mL (593.33 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (12.36 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (12.36 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: 2.5 mg/mL (12.36 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity. SDMA, a novel kidney biomarker, permits earlier diagnosis of kidney disease than traditional creatinine testing.

IC₅₀ & Target

Human Endogenous Metabolite

In Vitro	SDMA is the structural isomer of the cardiovascular risk marker asymmetric dimethylarginine, as an endogenous marker of renal function. SDMA does not directly inhibit NOS but is a competitor of arginine transport. SDMA is primarily eliminated by renal excretion and is a promising endogenous marker of glomerular filtration rate ^[1] . SDMA inhibits dose dependently the NO synthesis in intact endothelial cells, whereas it has no effect on protein expression of NOS ^[1] . SDMA is involved in the inflammatory process of chronic kidney disease, activating NF-κB and resulting in enhanced expression of IL-6 and TNF-α ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	SDMA is highly stable in serum and plasma, and the assay demonstrates excellent analytical performance. In unaffected dogs, SDMA remains unchanged whereas in affected dogs, SDMA increases during disease progression, correlating strongly with an increase in sCr and decrease in GFR ^[3] . Chronic SDMA infusion leads to a significant increase of SDMA levels in mice, but the GFR did not change at 4 weeks. No histological changes are observed, particularly no effect on fibrosis or endothelial nitric oxide synthase expression. There is neither an effect of SDMA on systolic blood pressure nor on ejection fraction ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[2]	SDMA stock solution is prepared in 0.9% NaCl and diluted in the cell culture medium or in heparinized whole blood resulting in a maximal uremic concentration of 6.1 μM SDMA. Whole blood is incubated with saline (control) or different doses of ADMA (0.6, 3.6, and 36 μM) or SDMA (1.5, 3.1, and 6.1 μM) for 2 hours in a humidified atmosphere of 5% CO ₂ in air at 37°C. Cells are finally stained for intracellular TNF-α or IL-6. Samples are analyzed with a flow cytometer ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[4]	Mice: Eight-week-old male C57Bl/6 mice receives vehicle-controlled infusion of SDMA (250 μmol/kg/days) for 28 days using osmotic minipumps (n=24/group). Glomerular filtration rate, cardiac function and blood pressure are monitored. Blood samples for SDMA determination are obtained at baseline, 2 and 4 weeks. Mice are euthanized at 4 weeks to obtain tissue for renal histology ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Bode-Böger SM, et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease.
- [2]. Schepers E, et al. Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. *Clin J Am Soc Nephrol.* 2011 Oct;6(10):2374-83.
- [3]. Nabity MB, et al. Symmetric Dimethylarginine Assay Validation, Stability, and Evaluation as a Marker for the Early Detection of Chronic Kidney Disease in Dogs. *J Vet Intern Med.* 2015 Jul-Aug;29(4):1036-44.
- [4]. Veldink H, et al. Effects of chronic SDMA infusion on glomerular filtration rate, blood pressure, myocardial function and renal histology in C57BL6/J mice. *Nephrol Dial Transplant.* 2013 Jun;28(6):1434-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA